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Background: Research suggests glial cells of different classes play a central role in schizophrenia 
pathology. The glial perspective may help to better understand and treat underlying mechanisms. 
This master thesis investigated hypothesized group differences in activation in glial markers N-
acetyl aspartate acid, myo-inositol and choline, with further exploratory analysis to symptom type 
and severity, peripheral inflammation-markers, and to diffusion tensor imaging (DTI) measures. 
Methods: The glial markers were acquired from magnetic resonance spectroscopy (MRS) imaging 
and processed with LCModel in four voxel placements. Clinical symptoms were indexed by the 
Positive and Negative Symptoms Scale (PANSS). Luminex Screening Human-Magnetic assayed 
inflammation-associated markers CRP and cytokines. The DTI data were processed using FSL and 
Tract-Based Spatial Statistics. The analysis included seventy-seven schizophrenia patients and 
controls (total N = 154) matched on age 18-65 (M = 30.23, SD = 10.23), handedness and gender 
(23,38% female). The results:  Significant higher overall choline in patients compared to controls 
and voxel placement interaction effects for NAA in anterior cingulate cortex was found. There 
were trend-level myo-inositol and group interaction effects on the FA values. The relationship was 
negative in patients, and positive in controls. The results from the regression models indicated that 
it is difficult to predict positive and negative symptoms by glial markers as well as predicting glial 
marker levels by inflammation markers, after adjusting for known moderating factors. Discussion 
and conclusion: The study had limitations and technical issues. The group differences suggest 
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Bakgrunn: Forskningsresultater foreslår ulike typer gliaceller som sentrale i schizofreni patologi. 
Fremvoksende litteratur indikerer at gliaperspektivet kan bidra til å bedre forståelse og behandling 
for lidelsen. Denne masteroppgaven undersøkte hypotesen om gruppeforskjeller i aktivering i 
assosierte gliamarkører N-acetylaspartate acid, myo-inositol og choline, med videre utforskende 
analyser til symptomtype og alvorlighetsgrad, samt til perifere inflammasjonsmarkører, og til 
diffusjonsvektet avbildning (DTI). Metode: Gliamarkørene ble målt med magnetisk resonans 
spektroskopi-vektet (MRS) avbildning og prosessert med LCModel i fire vokselplasseringer. 
Kliniske symptomer ble registrert av Positive and Negative Symptoms Scale (PANSS).  Luminex 
Screening Human Magnetic Assay analyserte inflammasjonsmarkørene CRP og cytokinene. DTI 
data ble prosessert med FSL og Trakt-Basert Spatiell Statistikk (TBSS). Analysen inkluderte 
syttisyv schizofrenipasienter og kontroller (N = 154) matchet i alder (M = 30.23, SD = 10.23), 
håndbruk og kjønn (23.38% kvinner). Resultater: Det ble funnet signifikant høyere nivåer av 
choline i pasienter sammenlignet med kontrollpersoner, og vokselplasseringseffekter for NAA 
knyttet til anterior cingulate cortex. Det var trendnivåfunn for myo-inositol og gruppe-
interaksjonseffekter på FA verdiene. Assosiasjonen var negativ i pasienter, og positive hos 
kontrollpersoner. Resultatene fra regresjonsmodellene indikerte vanskeligheter med å predikere 
positive og negative symptomer, samt for prediksjon av glialmarkørnivåer gjennom cytokiner og 
CRP, etter justering for kjente modererende faktorer. Diskusjon og konklusjon: Studiet hadde 
flere begrensninger og tekniske problemer. Gruppeforskjellene foreslår gliadysfunksjon, noe som 
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Schizophrenia and Glial-Inflammation Activation: A brief introduction 
Schizophrenia is a severe mental illness compromised by several disease phenotypes 
mainly associated with an inability to distinguish mind from environment, overall causing heavy 
disability for those affected. The underlying pathologies and mechanisms remain unclear. 
Converging evidence from neuropathological, biochemical and genetic studies suggests that glial 
cells of different classes could be involved in neuroinflammation, and hence could be one of the 
disease mechanisms playing a central role in schizophrenia pathology. Summing up the evidence, 
it is evident that the “glial perspective” may help to better understand the disease and identify 
promoting mechanisms and potential medication targets (Bernstein, Steiner, Guest, and Bogerts, 
2014).  Several studies and meta-analysis on inflammation mediators in schizophrenia is 
concluding with increased levels of cytokines that may reflect glial cells microglia and astrocyte 
activation in the central nervous system (Rothermundt et al., 2007). Inflammation is in the past 
decades increasingly investigated in association to schizophrenia as inflammation is increasing 
suggested to be a moderating link between genes and environment. Identifying schizophrenia-
related biomarkers could aid earlier diagnosis and guide targeted personalized therapies. This 
project investigate the relationship of glial markers in brain in schizophrenia, and to inflammatory-
associated markers in peripheral blood, as well as explore the relationships of the markers with 
positive and negative symptoms. 
 
Schizophrenia  
Schizophrenia has identifying features of positive and negative symptoms, yet is a 
heterogeneous population in terms of manifestation, course and duration, with a range of indicated 
mediators and potential origins in manifold. According to World Health Organization, it ranks top 
10 worldwide disability and counts 3% of global burden (World Health Organization, 2015). 
Remaining an unresolved problem as cognitive deficits makes living with schizophrenia highly 
disabling, and one of the gravest mental diseases among young adults, intense effort is made to 
relive the affected (Wieronska, Zorn, Doller, and Pilc, 2016).  
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Regarding the manifestation of schizophrenia, the positive symptoms at core entails lost 
contact with reality, i.e. delusions and hallucinations. The most common type of hallucination 
involves hearing voices, and also see and smell other things that are not here. Delusions could be 
exemplified in people think they are someone famous or have special powers, or that they are being 
surveilled or foresee terrible future. The negative symptoms expresses as impaired motivation, 
social withdrawal and reduction in spontaneous speech, together with poorer cognitive 
performance compared to controls (Joyce and Roiser, 2007). The communication may not make 
sense or be meaningless, or give answers that are unrelated to the questions asked.  Overall, 
cognitive impairment is key as it concerns thought, perception and memory, all found significantly 
aberrant in patients. “Cognition” as a term is understood as the ability to process information (Latin 
= to know, recognize) (Mitterauer, 2011), which is clearly impaired as the typically most 
characteristic symptom in the illness is the failure of differentiating between inner and outer world. 
Cognitive function has underlying mechanisms in a complex relation set between networks, 
potentially driven by various neurotransmitters, glial cells and neuromodulators (Miller et al., 
2010; Miller and Goldsmith, 2017).  
The term “schizophrenia” itself refers to a “splitting of mind” in Bleuler's original 
terminology (Bleuler 1950 cited in Phillips et al., 2003). Since its first description, the core features 
of split between thoughts (cognition) from feelings (emotion) together with flattening affect 
(anhedonia) is core to the experience (Bentall, 2013). Poor social skills and misinterpretation of 
social cues as revolving around the person instead for neutral and unrelated circumstances is often 
reported. Before onset, usually in early adulthood or late childhood, individuals are often 
considered normal except reports of vague experiences of own self and thoughts (Henriksen and 
Nordgaard, 2014). Increasingly difficulties with forming and understanding clear ideas, 
distinguishing relevant and irrelevant information and time conception are distorted (Cameron, 
Robertson and Nordahl, 1992). These are examples of cognitive symptoms, as it reflects lack of 
attention and memory (Silver and Feldman, 2005), and overall could be referred to as a “thought 
disorder”. In the behavioral aspect, people may make strange postures or unpredictable actions.  
Furthermore, the lack of differentiating objects and individuals in environment from oneself, as 
patients experience what is taking place in the brain as real; it could be referred to as a loss of 
conceptual boundaries (Mitterauer, 2011).  Overall, schizophrenia as a disintegration of the 
experience of self is a conceptualization shared among many researchers (Kean, 2009; Postmes, 
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Sno, Goedhart, Van Der Stel and Heering, 2014). Living with distortions are highly debilitating to 
the patients. The illness affects the ability to engage with others in socially acceptable ways, and 
to take care of themselves. As cognitive and negative symptoms precede positive manifestation, 
studies are aiming to entwine the distinct underlying mechanisms of the clinical manifestations.  
Due to the heterogeneity in the population and the likelihood of several causing factors, 
one can speak of schizophrenia as a syndrome. Current research sums the disease to be statistically 
heritable, yet non-Mendelian, with possible roots in neurodevelopment deficits and epigenetic 
dysregulations of the brain genome playing a fundamental role in the course and manifestations of 
the disease that will be further discussed. Emerging models propose a disruption of the main 
systems in glial-neuronal interactions (Mitterauer, 2011), and research on neuroinflammation is 
promising for identifying potential mediating processes at work in schizophrenia.  
 
Diagnosis and treatment. 
Among the tools for assessing severity and presence of schizophrenia-associated 
symptoms, the positive and negative symptoms scale (PANSS; Kay et al., 1991) measures, in 
addition to the former mentioned characteristic positive and negative symptoms, also more general 
psychopathic themes like somatic concern and depression, as well as items addresses agency in 
the patients. Most patients experience thoughts to appear automatically and not coming from 
oneself. Furthermore, as diagnosis is currently relying merely on interview, which is often 
critiqued to be prone to subjectivity, more objective assessments like the use of biomarkers, is 
warranted (Horváth and Mirnics, 2014). Moreover, there is a great heterogeneity in symptom 
manifestations; it could be difficult to distinguish from other mental illness, such as bipolar 
disorder (Lichtenstein et al., 2009).  
As of currently, there seems to be no cure for schizophrenia (Piltman, 2018), yet many find 
relief in medication, however, some patients are treatment resistant (Kroken et al., 2014). 
Concomitant treatment, like cognitive behavioral therapy and social skills training together with 
antipsychotic medication is suggested among the most optimal interventions as of now. Most 
patient has a lifelong diagnosis with poor prognosis where most relapse after a few years (Johnsen, 
Kroken, Wentzel-Larsen and Jørgensen, 2010), with interindividual variations in remission and 
relapse.   
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Regarding medical treatment, theories of the pathophysiology underlying schizophrenia 
have centered on neurotransmitters and their receptors, and therapeutic drug development has 
largely targeted dopamine, serotonin and glutamate systems (Kroken et al., 2014).  Antipsychotic 
drugs remains as the pillar in the treatment, yet has small effect sizes in the cognitive domain 
(Bruijnzeel, Suryadevara, and Tandon, 2014), with the primary effect in reducing the positive 
symptoms. With short-term effectiveness, the vast majority of the patients experience decline in 
improvement along with increase in side effects (Johnsen, Kroken, Wentzel-Larsen & Jørgensen, 
2010). Certain drugs, especially clozapine and olanzapine, are reported to give adverse metabolic 
effects such as weight gain, hyperglycemia and hypertriglyceridemia (Johnsen et al., 2010, Kroken 
et al., 2014). It is suggested that the elevated mortality within the patient group could be due to 
side effects contributing to physical illnesses, like cardiovascular diseases, diabetes and cancers 
(Cullen et al., 2012). Furthermore, medication is found to have detrimental effects like brain 
volume loss as indicated by a longitudinal volumetric study, indicating heavy influence by 
medication dosage (Ho, Andreasen, Ziebell, Pierson and Magnotta, 2011). Hence, identifying 
alternatives is of great interest.  
 
Brain abnormalities in schizophrenia. 
Several brain abnormalities are associated with schizophrenia. The functional deficits in 
schizophrenia suggests abnormalities in the brain as it parallels with evidence of dysconnectivity 
revealed by fMRI and DTI, together with abnormal structures such as enlarged ventricles as 
indicated by sMRI (Elkis, Friedman, Wise and Meltzer, 1995). Another line of research that 
includes post-mortem and genetic studies has demonstrated myelin-related abnormalities in 
schizophrenia, which further suggests not only functional but also anatomical disconnection 
between brain regions (Hakak et al., 2001). The correlation between the typical onset in teenage 
years or early adulthood and maturation of glial cell-derived myelin fits with the idea of faulty 
brain trajectories that manifests when conduction velocity is comprised (Fields, 2008).  
Characteristic symptoms of schizophrenia like auditory hallucinations is one example of a 
symptom that is running parallel to myelin and white matter condition. White matter is hence 
suggested to be a potential reliable biomarker of schizophrenia. Biomarkers Definitions Working 
Group (2001) defines biomarkers as a characteristic that objectively measured and for them to be 
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evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological 
response to an intervention. Genes, gene expression products (transcripts and proteins) and 
metabolites are the main biomarker families (Rodrigues-Amorim et al., 2017.). In schizophrenia, 
aberrant EEG signal (e.g. Kompus et al., 2015), and structural and functional abnormalities 
indicated by MRI as previously mentioned are among the previously suggested biomarkers.  
It is implied that brain abnormalities are among the underlying reasons for auditory 
hallucinations. Hearing voices is not exclusive to schizophrenia yet is the most characteristic 
feature occurring in 70% of patients (Hugdahl, Løberg & Nygård, 2009) and remain the most 
researched symptom. Auditory hallucinations (AHs) are also reported in mood disorders, 
personality disorders, post-traumatic stress disorder as well as in the general (non-clinical) 
population (Water, Blom, Jardi, Hugdahl and Sommer, 2018). Interestingly, the content and form 
of the auditory verbal hallucinations appear similar, however the response varies considerably with 
emotional valence being found as a predictor of functioning (Daalman et al., 2011).  A difference 
in mean age onset for auditory hallucinations (AH) between healthy (12.4 years, SD = 13.6) and 
psychotic patients (M = 21.4 years, SD = 11.7) has been found (Dalmaan et al., 2011). This might 
be indicative of a difference in etiology within schizophrenia patients, something that have been 
interpreted by some authors to imply sub-types in the syndrome (Geisler et al., 2015). Synaptic 
density peaks during childhood, followed by extensive decrease of neuronal connectivity (pruning) 
during adolescence. Hence, the younger onsetters could be understood as a manifestation of 
maximal synaptic density, while the schizophrenia-related AHs are associated with aberrant 
synaptic connectivity obvious after myelin maturation. Such interpretations could aid in the 
differentiation of subtypes when similar manifestations occur. 
In studies with children with early onset, not only did the subjects cross threshold of 
behavior, but abnormal evidence apparent also on brain imaging level (Hoffman & McGlashan, 
2001). One study found abnormalities on a brain level in particular in superior temporal gyrus 
(STG) and dorsolateral prefrontal cortex (DLPFC) (Thompson et al., 2001). Findings like these 
have been interpreted as compelling evidence for the condition to be a brain disorder, in which 
behavior is the last thing to change (Insel, 2015). Hence investigating the biological architecture 
is a goal among researchers and research groups (e.g. NORMENT). 
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The Glial Perspective 
Glial cells, inflammation and schizophrenia. 
Structural, molecular and functional changes in glial cells is of interest as studies are suggesting 
abnormalities in all three types of glial cells (Bernstein et al., 2014). Exploring the immune 
signature in schizophrenia could aid for a better explanation, diagnostics and treatment. In 
degenerative and inflammatory illnesses, huddles of glial cells are found around malfunctioning 
neurons, which may either work as protectors and aid in restoration, or be neurotoxic when over-
activated without stopping (Block, Zecca and Hong, 2007). Brain imaging and genetic analysis 
have yielded a wide range of glial cell-associated white matter abnormality data in schizophrenia 
(Takahashi, Sakurai, Davis and Buxbaum, 2011). White matter consists of myelin, which is 
produced by oligodendrocytes, one out of three major types of glial cells. Overall, neuroscience 
research suggest schizophrenia as a dysconnectivity syndrome, and as white matter forms 
connections between brain regions, and impaired connectivity indicated by reduced fractional 
anisotropy is a typical finding (Kubicki, Westin, Pasternak and Shenton., 2005), the role of glial 
cells seems pivotal. Glial cells have functions far beyond merely myelin production, like 
microglia’s ability to produce pro- and anti-inflammatory reactions.  An increasingly large body 
av research have found microglia activation in schizophrenia patients differing from controls, 
contributing to the formulation of a presence of low grade inflammation, or the “mild encephalitis” 
hypothesis as proposed by Bechter (Bechter, 2013). Several factors are identified to moderate and 
mediate schizophrenia, yet the majority of people do not develop schizophrenia despite being 
exposed to risk factors. Hence, the illness is interpreted to be mitigated by interactions across 
genetics, epigenetic and environmental risk factors (Miller et al., 2012).  
Immune functions. 
Anomalous immune function is increasing hypothesized involved in the pathophysiology 
of schizophrenia and could be of paramount importance as the mechanisms could be the missing 
link between genetic disposition and environmental factors, and its biological manifestations 
(Watanabe, Someya and Nawa, 2010). Increasing focus has been given to inflammation 
mechanisms the past decades, both genetic and environmentally derived, in particular during 
embryo state (viral infections, lack of nutrition, drug use) and trauma during birth such as neonatal 
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infections as well as hypoxia and autoimmune diseases (Brown, 2011). The presence of 
inflammation markers is demonstrated in peripheral blood, in cerebrospinal fluid (CSF), as well 
as in white and grey matter in schizophrenia (Najjar and Pearlman, 2015).  
Inflammation is the complex biological response of inflammatory cells to pathogens, 
damaged cells or irritants. When inflammation occurs stereotypically as a response, it is referred 
to as the innate immunity in contrast to adaptive immunity that is specific to each pathogen, as in 
the example of vaccination against specific diseases. Both the acute response to damaging stimuli 
and the chronic one gives progressive change in the types of cells present at the location of 
inflammation, which is characterized by both destruction and healing of tissue (Horváth & Mirnics, 
2014). Sources to inflammation could be environmental such as virus and bacteria, nicotine, 
pollution and obesity (Prasad, Tyagi, & Aggarwal, 2016), yet it also indicated in psychological 
sources such as stress, both short-term and prolonged (Watanabe et al., 2010). It is a known fact 
that the immune system is activated during normal stress response to prepare the body for being 
most adequate for action, which is a positive and normal response, however, it could become 
pathological if the response is not “switched off”. However, there are also instances where the 
immune system is activated targeting the body itself, as in autoimmune disorders like HIV. 
However, reviewers are pointing to the nuance that the inflammation in schizophrenia is modest 
in comparison to inflammation pathologies like the example of HIV and rheumatoid arthritis 
(Serhan & Savill, 2005), and hence is often referred to as “low-grade” inflammation. 
 
The Glial Cell Classes. 
Each of the three glial cell classes - oligodendrocytes (OC), astrocytes and microglia are 
all found to confer a unique contribution to the pathophysiology of schizophrenia. Glia, or 
neuroglia, are non-neuronal cells engaged in the inflammation system and functions in maintaining 
balance in the body (i.e. homeostasis), forming myelin and support and protect neurons (Kroken 
et al., 2012).  
Oligodendrocytes. 
In schizophrenia, several studies are concluding that white matter is abnormal, supported 
by findings of lacking more oligodendrocytes than in normal in several brain regions. Myelin is 
the main component in white matter and is produced by oligodendrocytes. Myelin is essential for 
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the quality of conduction along the axons, synchronizing brain signals and contributing to synapse 
plasticity (Fields, 2008). Few of the developmental processes continues into adulthood, yet 
myelination is an exception. The development is later completed in women, a phenomenon that 
also is parallel in the gender differences in the onset of schizophrenia-related symptoms (Häfner, 
2003). The temporal correlation of completion of myelination and disease onset suggests the debut 
to reflect maturation of myelinated tracts and manifests in misconnected networks (Davis et al, 
2003). Studies are indicating underlying differences in onset of schizophrenia: the earliest onset 
cases are found to have more severe white matter abnormalities in contrast to the more regular 
early adulthood onset (Douaud et al, 2007; Szeszko et al., 2008) while less white matter changes 
were reported in late-onset (Jones et al., 2005). These findings might be the cue to the great 
heterogeneity in the pool of schizophrenia as there might be important differences among clinical 
subgroups that may manifest as different white matter pathology (Chen et al., 2013).  
Fractional anisotropy (FA) is one of the most common indices of white matter representing 
the degree of spatial coherence in the fiber tracts. The FA value is altered by changes in the 
microstructure caused by for instance demyelination and inflammation (Alexander, Lee, Lazar and 
Field, 2007). One of the strongest supports for schizophrenia as a dysconnectivity syndrome stems 
from the replication of reduced FA in frontal and temporal lobes and in the fiber bundles that 
connect those (Roalf et al., 2013). However, the reduction is not limited to those areas, but also 
reported in parietal and occipital regions, which has been overall interpreted as global white matter 
alteration in schizophrenia (Roalf et al., 2013).  
Astrocytes. 
Astrocytes are actively controlling neuronal activity and synaptic information transmission 
(Mitterauer, 2011). They play a crucial part in supplying neurons and OCs  with content for energy 
metabolism as well as a range of functions such as regulating neurotransmitter release, modulating 
the immune response and expressing neuromodulators (Sofroniew and Vinters, 2010), and several 
of astrocyte genes are found altered in schizophrenia. Furthermore, astrocytes is also implicated in 
the known dopamine dysregulation, and medication is thought to influence a hypothesized 
disturbed astrocyte metabolism (Kondziella, Brenner, Eyjolfsson and Sonnewald, 2007).  
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Astrocytes and oligodendrocytes: partners in crime? 
There are overlaps in myelin deficits and neurotransmitter alterations. The role of glial cells 
is of pivotal importance for neuronal migration and synaptic functions such as glutamatergic and 
N-methyl-D-aspartate (NMDA) regulation, and abnormalities in such is indicated caused by 
astrocyte dysfunction (Bernstein et al., 2014). Their dysfunction could have detrimental impact 
such as reducing neuronal size, reducing levels of synaptic proteins as well as abnormalities in 
neurotransmission and functional dysconnectivity. Alterations in dopaminergic transmission as 
well as the glutamatergic system has long been investigated and implied in the disease’s pathology. 
The observations of behavior similar to  positive symptoms in schizophrenia induced by 
psychoactive drugs such as cocaine and amphetamines affecting glutamatergic N-methyl-D-
aspartate (NMDA) receptor antagonistic dopaminergic activity on these D2 dopamine receptors 
was the origin to the neurotransmitter imbalance hypothesis of dopamine and glutamate (Snyder, 
1973 cited in Kolb and Whishaw, 2001). Further neurochemical conceptualization stems from the 
effects of glutamate receptor antagonists like phencyclidine (PCP) and ketamine producing both 
positive and negative symptoms, giving rise to the glutamate hypothesis, which stands in 
complement to the dopamine hypothesis (Gilmour et al., 2012). Altogether neurotransmission and 
tissue ties in loop as it is found that when glutamate is in excess it is damaging to myelin, (which 
is one suggestion to the abnormalities observed and progressive worsening (Walterfang et al., 
2011).  
Microglia. 
Microglia cells are the predominant macrophages in the brain, making up 10% of the brain 
(Wood, 2003), executing three different morphologies of resting, activated or phagocytic state 
(Doorduin et al., 2005).  Activated microglia are core to neuroinflammation for their role in 
removal of damaged tissue and infectious agents. Beyond phagocytosis, activated microglia also 
stands for cytokine production and is involved in the kynurenic acid (KYNA) pathway, which is 
connecting to serotonin and glutamate neurotransmitter systems (Kroken et al., 2014), two 
neurotransmitters traditionally important in the conceptualization and treatment of schizophrenia.   
It is argued that microglial activation can distort neurotransmission, and hence be a source 
of psychotic symptoms (Steiner et al., 2013). Subtracting for such suggestions, their relation to 
PANSS symptoms index is indicated as likely and an interesting field to explore. The mechanisms 
behind the symptom manifestation and glial activation is suggested to lie in how microglial-
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derived cytokines IL-1beta and IL-2 both have the ability to modulate catecholamine levels in the 
brain (Labuzek et al., 2005). Hence, microglia is important in neuronal protection as a reactant to 
pathogens, however, also in pathology when not deactivated (Block et al., 2007). Overall, 
microglia is the primary source of pro- and anti-inflammatory cytokines, which makes microglia 
a key player in neuroinflammation with the ability to produce or mediate a wide range of cellular 
responses (Kraft and Harry, 2011).  
Cytokines. 
The cytokine hypothesis of schizophrenia is deriving from a range of studies indicating 
abnormalities in the cytokine network, which might contribute to the neurodevelopmental and 
neurodegenerative findings previously presented in this master thesis.  
Cytokines are key signaling molecules acting as regulators of acute and chronic 
inflammation, exerting their effects in the periphery and brain. This makes them a main connection 
between the central nervous system and immune system (Kubistova, Horacek, and Novak, 2012). 
Their ability to cross talk between the brain and immune system have be interpreted to highlight a 
gene-environment interaction in schizophrenia (Maric and Svrakic, 2011). Cytokines are deriving 
from both immune and nonimmune cells, binding to specific receptors on a range of target cells. 
When proinflammatory cytokine family, like interleukin (IL)-1beta, IL-6, and tumor-necrosis 
factor alpha (TNF-alpha) are activated, they facilitate vascular permeability and promote release 
of mediators that are a part of the complement system of immune functions. Under normal 
conditions, inflammation is controlled by homeostatic mechanisms.  However, dysfunction in the 
feedback mechanisms that identifies whether the triggering processes is removed which further 
allows for anti-inflammatory repair process, leads to persistent inflammation. Dysfunction as such 
is observed in illnesses like rheumatoid arthritis, multiple sclerosis and Crohn's disease (Serhan & 
Savill, 2005). The low-grade inflammatory response observed in schizophrenia, both in central 
nervous system and in peripheral blood is suggested to be a result of disrupted blood-brain barrier 
(BBB), which is an important protector against pathogens, are is found important in 
neurodevelopmental and neurodegenerative diseases like the former mentioned, and is also found 
indicated aberrant in schizophrenia (Stolp and Dziegielewska, 2009).   
Of the anti-inflammatory mechanisms, IL-10 is the hallmark of high antibody activity, also 
referred to as type 2 immunity (Spellberg & Edwards, 2001). Type 1 is high the phagocytic 
activity, which is suppressed by IL-10 and other t-helper type 2 cells. In immunosuppression or 
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severe systemic stress, the immune system responds with a Type 2 reaction. In other brain 
disorders such as formerly mentioned MS as well as Alzheimer’s disease, immune cells is thought 
to cross the blood brain barrier (BBB) into brain tissue and when unregulated/dysfunctional, is 
found damaging. Microglia cells produce mainly type 1 immune response in the form of secreting 
cytokines like IL-6, while astrocytes produce type 2 cytokine IL-10 (Bernstein et al., 2014). 
The direction of expression of the cytokines are not completely consistent within the 
literature. Overall, IL-1beta, IL-6, IL-10 and TNF-alpha, are among the cytokines found abnormal, 
however, their direction varies. TNF-alpha was found elevated in two studies both for chronic 
medicated patients and for first-episode unmediated patients (Boyajyan, Zakharyan and 
Khoyetsyan, 2012; Drexhage et al., 2010). However, other studies have found a decrease and 
others again found no change (Davison et al., 2016).  
Furthermore, studies are indicating links between different markers and symptoms. For 
instance, IL-6 is in particular found associated to sustained attention (Holden et al., 2011 cited in 
Meyer et al., 2011). IL-12 and TNF-alpha is found elevated throughout illness duration, which is 
proposed by Miller and colleagues (2011) to be indicative as trait markers. TNF-alpha is thought 
to contribute to schizophrenia in its activation of the hypothalamic-pituitary-adrenal (HPA) axis 
as well as neurotoxic release of glutamate (Himmerich, Berthold-Losleben and Pollmächer, 2009).  
Overall, it is generally suggested that member of the cytokine network may contribute to 
the pathogenesis of schizophrenia. In a meta-analysis, 40% of patients were found to have some 
form of inflammation (Osimo, Cardinal, Jones and Khandaker, 2018). Furthermore, in a summary 
of 99 studies, it was found that in 50% of the included studies, IL-6, TNF-alpha, and IL-1beta, was 
found to differ between patients and controls (Rodrigues-Amorim et al., 2017). Importantly, the 
identified changes are small, in particular in comparison to higher-grade inflammation like 
autoimmune disorders, again underlining schizophrenia as a low-grade inflammation. 
CRP. 
As a regularly accepted and applied biomarker for acute phase inflammatory response, C-
reactive protein (CRP) has been used for diagnosing, monitoring treatments and progression in 
post-surgical situations (Kroken et al., 2014). CRP is synthesized in the liver as a main reactor to 
tissue damaging processes (Fathian et al., 2019). Cytokines IL-1beta, IL-6, and TNF-alpha among 
others, are indicated as main stimulators for the production of CRP and other acute-phase proteins 
(Wigmore et al. 2011, cited in Zakharyan and Boyajyan, 2014).  In past years, it is found an inverse 
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relationship between CRP and cognitive performance in schizophrenia patients (Johnsen et al., 
2016), and is consistently found elevated even in some studies across illness duration irrespective 
of medication status (Fernandes et al., 2016). One study suggested that IL-6 and CRP impair 
anisotropy in certain fiber tracts that are repeatedly found aberrant in schizophrenia patients, like 
inferior longitudinal fasciculus, and that the variation of the impact from the immune mediators 
suggests differences in their effect across the fiber pathways (Prasad, Upton, Nimgaonkar & 
Keshavan, 2014).  
In conclusion, inflammatory mechanisms makes a healthy reaction yet may be a 
detrimental contribution to pathology, as proinflammatory cytokines plays a part in both 
neurogenesis and synaptic transmission, as well as cell death. The latter activation is found to have 
adverse effects, which manifests as the characterizing factors of several neurological disorders, 
such as in multiple sclerosis where myelin in destroyed (Hemmer, Kerschensteiner & Korn, 2015).  
Biomarkers of glial cell activation. 
Recent studies expand the research on glial cell markers by investigating in the brain in 
vivo with the aid of proton magnetic resonance spectroscopy (h-MRS). Studies suggest that 
neuroinflammatory disorders are related to elevated glial markers such as myo-inositol (mI) and 
Creatine and Choline, while concentration of neuronal metabolites like Glutamate and N-Acetyl 
aspartate Acid (NAA) are reduced (Reid et al., 2010). However, it is important to take note that 
normative metabolite concentrations are dependent on important clinical variables, such as age 
and gender, and there are individual differences (Chang et al., 2013). For instance, normal brain 
aging is associated with increased neuroinflammation, which in turn may lead to higher levels of 
glial metabolites like mI and Creatine in certain regions. This highlights the importance of 
matching the subjects in studies with MRS on age, gender and voxel placements in the brain 
regions. Three metabolite markers, choline, NAA and mI, are of particular interest.  
Being the strongest in concentration in glia cells compared to neurons, choline is regarded 
in the research field as a glial cell marker. Choline is associated with inflammation in the light of 
the presence of more choline in glial cells which activation in triggered by inflammation and hence 
more choline must mean increased glial cells, which produce inflammatory mechanisms 
(Bernstein et al., 2014). Choline in the brain is higher than in plasma, but is dependable on the 
plasma concentration as the latter in influenced from and to peripheral organs. When cholinergic 
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neurons are activated, certain kinds of nutrition can increase acetylcholine release (Ross et al., 
2010). Choline could also be understood as a marker of cell density, and reflect changes in 
phospholipid membrane formation (Chang et al., 2013). In general, studies have found higher 
choline in patients compared to controls (e.g. Plitman et al., 2018). 
When glia are activated the cell volumes are enlarged which tend to correlated with 
elevated myo-inositol (mI) (Kantarci et al., 2008). mI is involved in maintenance of cell osmolality 
and phospholipid metabolism (Moore et al., 2000) and is evaluated as a glial cell marker due to 
higher expression in glial cells than neurons (Mahli et al., 2002). mI is further associated with 
aging, in that it increases with time. In neuroinflammation mI is increased and this might be taking 
part in hypomyelination, similar to the processes in MS. Decreased mI was found correlated to 
depressive symptoms which have led researchers to interpret it as a biochemical marker for such  
(Chiapelli et al., 2015). Otherwise, a potential target as administration have shown to improve 
mood in healthy volunteers (Moore et al., 1999).  
 N-acetyl aspartate acid (NAA) is found decreased in demyelination diseases such as 
multiple sclerosis (MS) and is associated with axonal injury (DeGraaf, 2011). Findings of reduced 
NAA in schizophrenia in medial temporal regions together with reduced anisotropy index is 
interpreted as lowered connection and myelination in axonal bundles (Schneiderman et al, 2007), 
and is therefore indicated as a glial marker. NAA is reckoned as a marker for neuronal viability 
and integrity, however it can be misleading to conceptualize is as structural marker (Reid et al., 
2010). Due to its ability to recover should rather be viewed as a surrogate marker of neuronal 
health and dysfunction, rather than loss (Dwyer et al., 2018). In another study, specifically ACC 
was found to have lower levels of NAA compared to healthy controls (Reid et al., 2010). Overall 
is it thought to be more stable in healthy subjects with very low turnover and in general is prone 
to regional and developmental variations that might correlate with mental function (DeGraaf, 
2011).  
Models on glia and inflammation in schizophrenia. 
There are several popular models on glia and neuroinflammation activation in 
schizophrenia. One model presents that synapses with non-functional astrocyte receptors can lead 
to uncontrolled synaptic information flux as no neurotransmitter can communicate to the receptor 
(Mitterauer, 2011).  This model argues that it may cause a generalization of information processing 
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that may lead to manifestation of thought disorder such as hallucinations and delusions. It points 
to how the brain is unable to process information into categories when the oligodendrocyte-axon 
system is faulty. 
Another proposed model on the characteristics of inflammation occurrence in 
schizophrenia postulates how abnormal expression of the inflammatory genes produce peripheral 
inflammation caused by either stress or pathogens (Meyer et al., 2011). The outcome of microglia-
activated astrocytes releasing cytokines such as IL-6 and IL-10 that further leads to KYNA 
production, which block signaling to the NMDA receptor. Meanwhile microglia release cytokines 
IL-1beta and TNF-alpha, which ultimately promote production of neurotoxic substances. Further, 
the model proposes that irregular hypothalamus-pituitary-adrenal (HPA) axis function subsidize 
the inflammation, as there is a malfunction in the feedback-system. Pro-inflammatory cytokines 
has the power of mediating the activation of the axis, and this signaling is found to impair affective, 
emotional and social functions (Dantzer et al., 2008). This is expressed as for instance as flattened 
affect.  
Takahashi and colleagues (2011) propose in their model that alterations in 
oligodendrocytes and subsequently myelin induce hyper-dopaminergic states in frontal lobes 
(Takahashi et al., 2011). In normal states when an inhibitory neuron receives enough glutamate 
input, it release a sufficient amount of GABA to inhibit excess dopamine release at dopaminergic 
terminals. However, if the communication neuron has unmyelinated axons, the inhibitory neuron 
fail to release the correct amount of GABA and fails to inhibit the excessive dopamine release. 
Another model could explain why typical antipsychotic medication is effective on reducing the 
positive symptoms. Ren, Wang and Xiao (2013) reviewed the effects of both typical and atypical 
medication like, quetiapine and olanzapine, and found them to promote the maturation of 
oligodendrocyte, which subsequently can restore myelin. This contributes to the restoring of the 
hyperactivity of dopaminergic neurotransmission.  
Identifying Biomarkers in Schizophrenia with Imaging Methods 
Many techniques are available to investigate brain chemistry, but most are indirect 
measures and only shows a fraction of the potential contributing factors of the molecular, structural 
and functional components (Goff et al., 2016). To with accuracy be able to identify an individual 
based one biomarkers could be a critical agent in identifying the disease state, identifying factors 
 GLIAL ACTIVATION AND NEUROINFLAMMATION IN SCHIZOPHRENIA 
15 
contributing to underlying progression and predicting and monitoring response to treatment (Goff 
et al., 2016).  
Multi approach complementary techniques are increasingly being applied for research on 
schizophrenia for a fuller understanding of the underlying pathophysiology. Cell firing as in action 
potential can be studied to give information on how cells are connected, yet the chemical changes 
is also crucial for understanding cell communication. No technique measure the large number of 
chemical signaling, as there are discrepancies in time and length scales.  For instance, magnetic 
resonance spectroscopy (MRS) can measure biochemical profiles in the brain, whereas diffusion 
tensor imaging (DTI) is more sensitive to white matter structural differences. Further methods 
includes more traditional Structural magnetic resonance imaging (sMRI) revealing brain anatomy 
while functional magnetic resonance imaging (fMRI) highlights connectivity.  
Magnetic resonance spectroscopy. 
Magnetic Resonance Spectroscopy (MRS) is a non-invasively technique assessing the 
chemical metabolism/environment within a certain region of interest. While MRI identifies the 
anatomical location/tissue structure, MRS can compare the chemical composition of normal brain 
tissue to abnormal (DeGraaf, 2008). MRS exploit the magnetic properties of the hydrogen proton. 
The surroundings of the hydrogen proton(s), i.e., the molecule in which the proton is bound, 
influence its magnetic properties. This allows differentiation and identification of signals from 
different molecules. There are several metabolites, or products of metabolism, to evaluate. The 
frequencies of these metabolites are measured in units called pars per million (PPM) and can be 
visualized in a graph as peaks of varying heights (DeGraaf, 2011). 
In order for the signal to be detected, pulse sequences creates magnetization in the 
transverse plane. There are two techniques mostly applied; PRESS (point resolved spectroscopy 
sequence) and STEAM (stimulated echo acquisition mode). The PRESS is most preferred for 
longer echo times and at field strengths of 3 T or lower, whereas STEAM are preferred for higher 
field strengths. Many metabolites may be measured with short echo via PRESS; however, some 
compounds are hard to disentangle due to low biological concentration and significant overlap in 
spectral profiles with other signals that are stronger at the same frequency (Dwyer et al., 2018). 
GABA is one of such, which then required the application of MEGA (Mescher-Garwood) spectral 
editing implemented to the PRESS giving MEGA-PRESS.  To highlight some of the metabolites 
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available via MRS, there are neuronal markers like NAA and Glu, glial markers mI and Choline, 
and cell energy marker Creatine as well as inhibitory y-aminobutyric acid (GABA) (DeGraaf, 
2011). 
 
Figure 1: Example of H-MRS spectra, taken from ACC in the current sample. The top line is the 
PRESS measures. The most pronounced peaks are from left to right: choline, creatine and N-
acetyl aspartate acid (NAA) (red: patients, black: controls). The x-axis represents the unit parts 
per million (PPM) and the y-axis represents the various magnitude of the peaks. The lower line 
represents the MEGA-PRESS sequence.  
 
The x-axis values represents “chemical shift”: the frequency of the received signal, as a value 
relative to what is called Larmor frequency and is expressed in parts per million (ppm). The 
different metabolites has different peaks, as seen in table 1 and in figure 1. NAA is the most 
pronounced peak. The y-axis indicated the intensity of the signal produced. The intensity is related 
to the concentration of the signal in question, yet the relation varies between the metabolites. For 
instance, the NAA peak at 2 ppm as seen in the figure is four times higher than the 3.55 ppm of 
mI, but it does not mean that it is four time as much of NAA than mI (Craven, 2018, unpublished).  
Most of the signal from proton is in water (DeGraaf, 2011). The water signal is suppressed 
in the MRS sequences, which makes it easier to identify the weaker of the metabolite signals 
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(Gasparovic et al, 2006). Correction of cerebral spinal fluid (CSF) is required as well as correction 
distinguishing grey and white matter as the metabolite concentrations are found to vary with tissue 
type (Ernst et al., 1993 cited in Chang et al., 2013). Another important methodological factor is 
the use of reference marker as quantification typically relies on comparison to a reference signal 
(Dwyer et al., 2018). Cho or tCro is often used, however, they are both found to vary with age and 
stage of illness, which therefore might lead to drawing wrongful conclusions in the evaluation of 
spectral data/measures (Jansen et al., 2006 cited in Dwyer et al., 2018). Creatine is another 
typically used as internal reference as it has been considered a more stable metabolite. However, 
it has recently been found subject to gender effects, with particular variations with menstrual cycle 
(Hjelmervik et al., 2018). In this study, the authors point to how other studies use creatine as 
reference, yet the variations over the menstrual cycle is so prominent that it has important 
methodological implications for the use of creatine as reference, as uncritical use might bias results 
(Hjelmervik et al., 2018).  
 
Table 1: Typical resonances in ppm and concentration range in mmol/L for the glial marker 
metabolites and creatine (taken from DeGraaf, 2013) 
NAA: 2.0 PPM 7.5-17 mmol/L 
Choline: 3.2 PPM 0.5-2.5 mmol/L 
Myo-inositol 3.5 PPM 4-9 mmol/L 
Creatine: 3.0 PPM 4,5-10,5 mmol/L 
 
In conclusion, a force of researchers warrant further investigation of glial activation and 
neuroinflammation as altered neuro metabolite levels could be of clinical importance.  
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Assessing microstructure with diffusion tensor imaging. 
Diffusion Tensor Imaging (DTI) can be applied as a method for characterizing changes or 
differences with neuropathology and treatment as it is highly sensitive to changes at the cellular 
and microstructural level (Alexander et al., 2007). DTI detects the directional movement of water 
molecules to image nerve fibers in the brain, and the preprocessed image provides a reconstruction 
of water movement along axons that should correspond to actual fibers (Kolb and Whishaw, 2001). 
The direction of the water movement is detected by a coil and interpreted by a computer, which 
provides images that easily detects abnormalities in neural pathways.  
Two quantitative measures can be obtained from DTI: anisotropy indices and tract fiber 
orientations. Fractional anisotropy (FA) measure the amount of coherence of water diffusion, 
which reflects the amount of myelination in axonal bundles. Decreased anisotropy is interpreted 
as loss of integrity.  In a study, Seok, Kim and colleagues (2007) found positive correlations 
between hallucinations and FA within the superior longitudinal fasciculus, which includes the 
arcuate fasciculus. Note there are regular changes in FA during life span. Studies in normal ageing 
have uniformly shown decreased FA in late adulthood, predominately in prefrontal, temporal, 
parietal lobes and in the corpus callosum (Sullivan et al., 2006 cited in Seok et al., 2007), which 
are also the areas of last myelination as well as most vulnerable to myelin breakdown as 
consequence of normal ageing (Bartzokis et al., 2004 cited in Seok et al, 2007).  
Tract networks. 
In a previous study, particularly two anatomically and functionally connected networks 
were implicated in schizophrenia (Nestor et al., 2004). The frontal-temporal network includes two 
cortical regions, inferior frontal and anterior temporal areas, and these are connected by the major 
fiber tract uncinate fasciculus (UF) (Ebbling and von Cammon, 1992 cited in Nestor et al., 2004). 
The other network is connected via the cingulate bundle (CB), and consist of the amygdala, nucleus 
accumbens, and medial dorsal thalamus. This dorsolateral prefrontal–cingulate network is believed 
to extract information about task regularities and contingencies so that rules can be acquired to 
guide thought and action (Miller, 2000, cited in Nestor et al., 2004). This network is believed 
demonstrated aberrant in how Nestor, Kubicki, and colleagues (2004) found significant lower 
scores compared to controls across neuropsychological test scores on intelligence, declarative-
episodic memory, working memory and executive function. On the Wisconsin Card Sorting Test, 
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patients had a disproportionate number of perseverative errors relative to the controls. In the 
results, the left UF abnormalities, identified by DTI measures, correlated with deficits in 
declarative-episodic memory, but not in executive functioning. Whereas left CB abnormalities 
correlated with deficits in executive functioning, but not in declarative memory. The results from 
the study indicate a double dissociation between reduced DTI measures of the left UF and CB, and 
deficits in declarative memory and executive function, respectively. Taken together, such findings 
supports further a disconnection syndrome in schizophrenia.  
Overall, the different imaging modalities results give further understanding of the 
pathology in question. The combination of imaging with blood markers can give a more robust 
support to the potential presence of neuroinflammation. Abnormal tract geometry, 
neuroinflammation and demyelination as suggested pathologies might co-occur, being part of the 
same pathology, or might occur in succession. For instance, tract geometry might because of 
abnormal brain development predating schizophrenia especially for the early onsetters, followed 
by neuroinflammation (because of psychosis onset), and demyelination (a consequence of 
inflammation and/or disease progression).  
Statistics and Neuroscience 
The outcome of a study could lead to clinical trials that may affect many individuals, and 
it is therefore of importance that the methods used are as effective and correct as possible, with 
main fundament in model building.   
Imaging data are likely to not meet the assumptions of parametric tests, especially 
regarding distribution and random sampling, as research with such data often are comparing 
patients to controls, and the patients are not randomly selected participants. Increasingly, 
permutations test are applied for biological data as it makes fewer assumptions about the data 
(Winkler, Ridgway, Webster, Smith & Nichols, 2014). Permutations tests calculate all possible 
permutation of the data, and under the null hypothesis, use the outcome to estimate the distribution 
of the test statistic (Baume, 2015). This contributes to identifying critical areas, as there is a 
simulated null distribution. Randomization test within permutation tests refers to group 
membership being randomly assigned in the data, as in a null hypothesis where there are not 
difference between the groups, and when repeated multiple times, it simulate the null distribution. 
When there are not room for randomization, there must be week assumptions. With enough 
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replications run, typically 10000 iterations, the estimation of the distribution is argued to be very 
exact. To perform this, Permutation Analysis of Linear Models (PALM) is experimental software 
offering a range of methods, both parametric (e.g. MANCOVA) and non-parametric combination 
(NPC), and results in making fewer assumptions about the data like, offering statistics that are 
robust to heteroscedasticity (Winkler, Webster, Brooks, Tracey, Smith & Nichols, 2016). Classical 
methods based on means is not to be understood as invalid or without practical value. However, it 
could contribute to superficial understanding of the group comparison; some statecians argue 
(Wilcox and Rosselet, 2017). In sum, classical analysis methods are still used and valid, however, 
permutation methods, which only makes weak assumptions about the data, are increasingly applied 
and encouraged, especially for biological data (Winkler et al., 2014). 
 
The Current Project: Aims and Hypothesis 
Based on the studies reviewed in the introduction, it is clear that glial cell activation is associated 
to schizophrenia, and mostly differing from controls. The current project will focus on the glial 
activation related markers: choline, mI and NAA. To remind the reader, the three metabolites are 
considered glial markers due to choline and mI being higher expressed in glial cells than neurons 
(Bustillo et al., 2002; Mahli et al., 2002), and findings of reduced NAA in patients in medial 
temporal regions together with reduced DTI anisotropy index interpreted as lowered connection 
and myelination in axonal bundles (Tang et al., 2007). The current master project’s research design 
is mixed, both within and between subjects, with the aim of exploring glial activation in 
schizophrenia.  
The main investigation was hypothesized as 1) elevated levels of the glial activation markers mI 
and choline and decrease NAA in MRS spectra in patients compared to matched controls, with the 
glial markers acquired in 4 different locations across both hemispheres.  
The further analysis was exploratory for 2) within patients for associations between the 
glial activation markers to immune mediators in peripheral blood. We suggested running analysis 
with the pro-inflammatory markers IL-1beta, IL-6 and TNF-alpha, together with the anti-
inflammatory cytokine IL10 and CRP, fitted to prediction models in order to rule out a 0 hypothesis 
of no correlation between peripheral pro/anti-inflammatory cytokines and CRP to the glial 
markers.  
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Furthermore, the 3) symptom severity load indexed by two of the total scores from the 
Positive and Negative Symptoms Scale (PANSS) will be explored in relation to glial marker 
activation and the peripheral inflammation markers, as the literature are indicating impact on glial 
dysfunction on the symptoms, e.g. positive symptoms due to disconnection. 
The final analysis was  4) to examine whether the MRS-measured glial markers predict 
regional differences in fractional anisotropy (FA) values in diffusion-weighted images, and test 
for differences in this relationship in patients and controls.  If there are any significant 
group*marker interaction clusters, FA values will be extracted from these clusters and tested. 
Other studies have shown widespread lower FA in several brain regions in schizophrenia patients, 
indicating that white matter is in worse shape in patients. This could have to do with 
neuroinflammation, or demyelination. The tractograpy data indicate how strong the white matter 
tracts are between regions by the diffusion-coefficient fractional anisotropy (FA) in each voxel. 
The brain will be segmented into cortical areas and give estimated white-tracts between all of these 
to check for co-variance between identified tracts and the glial markers, i.e. the glial markers will 
be used as regressors to see which points in white substance have significant covariance between 









About the data 
The data used in the current master thesis was collected and granted by the Bergen Psychosis 
Project 2 (BP2), under the principal leadership of dr. med. Erik Johnsen. Over 200 patients were 
included in the BP2.  
Participants 
After quality control, MR spectra were available for seventy-six (77) schizophrenia patients (SZ), 
and 77 healthy controls (HC) matched on age (mean age = 30.23, SD = 10.23), gender (18 female, 
58 male) and handedness. Several structural and functional asymmetry differences exists between 
left- and right-handers (Sommer, Aleman, Ramsey, Bouma and Kahn, 2001). When not possible 
to match ambidextrous handedness, right-handed match was applied in line with other research 
done with the BP2 datasets (e.g. Hjelmervik et al., in prep). Age and gender are also crucial to 
match as they influence several biological variations, in particular white matter integrity and 
maturation (Alexander et al., 2007). The age was matched within +/- 3 years, except nine patients 
who were beyond this range (4-7 years). Patients and controls were also matched in terms of 
procedure protocols for scanning, as a scanner upgrade happened during the project duration. A 
subset of patients were MR-scanned repeatedly during follow-up; only the 1st session measures 
was included for the current study.  
  
Table 2: Medication exponation status. Measures for total 66 patients, missing nine.  
Never Not past year Not past 3 month Ongoing Started past 1-7 days 
26 2 2 29 7 
 
All patients were on medication at study start, with various exposure history (see table 2), and 
allocated to three different medications: amisulprid, aripiprazole and olanzapine. All patients were 
diagnosed with SZ according to the ICD-10 diagnostic manual (World Health Organization, 1992, 
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Norwegian translation; http://ehelse.no/standarder-kodeverk-og-referansekatalog/helsefaglige-
kodeverk/kodeverket-icd-10og-icd-11). The study was approved by the Regional Committee for 
Medical Research Ethics at the University of Bergen (REK no 2010-3387), and conducted 
according to the Declaration of Helsinki. All participants received oral and written information 
about the study before signing a written consent form.  
Exclusion criteria 
Before data collection, subjects were inhibited to participate on several grounds: inability to 
understand spoken Norwegian, psychosis due to neurological conditions or other diagnosed 
disorders such as bipolar, and pregnant or breastfeeding women, and being unable to use oral 
antipsychotics. 
Assessments 
At baseline, general demographics data was collected, together with history of mental and physical 
illnesses, smoking, and education. Symptom severity was assessed in interviews by trained and 
certified personal and translated into scores on the Positive and Negative Syndrome Scale 
(PANSS).  
PANSS (Kay, 1991). 
The PANSS consist of 30 items including 7 on positive symptoms, 7 on negative and 16 on general 
psychopathology. A total score is achieved by summing across the topics giving numbers ranging 
from 7 - 49 on the positive and negative, and ranging 16 - 112 on the general psychopathology. 
The scoring on the PANSS range from 1 being absent and 7 being extreme. As data is gathered, 
the interviewers considers firstly whether the item is present at all by its definition provided by a 
manual. The highest rating is chosen even if the patient meets criteria for lower point too whether 
or not all elements of the description are observed; a standard within research.  
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Image acquisition and processing. 
MRSI acquisition. 
Imaging data were collected with 3T GE-Signa MRI scanner at the Haukeland University Hospital. 
First, an anatomical T1-weighted image was acquired of each subject using a 3D SPGR sequence. 
This was used for voxel placement according to anatomical landmarks. There were two MRS data 
collection protocols, differing in voxel placements. Protocol 1 measured from left Superior 
temporal gyrus (STG), right STG and anterior cingulate cortex (ACC), and was applied for thirty-
nine of the patients and their matched controls. Protocol 2 recorded from left STG and left inferior 
frontal gyrus (IFG), performed on the remaining number of participants. Hence, all participants 
have obtained measures from left STG.  
 
 
Figure 2: Images of voxel placements in protocol 1: R STG (to the left) and ACC (right) in 
transverse view. The green box demonstrates the placement in one representative participant 
mapped onto a standard template. The orange and the red indicate respectively 95% and 60% 
confidence regions for the placements across the patient group.  
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For protocol 1, the following parameters were used: Repetition time (TR)/echo time (TE)/flip 
angle (FA)/inversion time (TI) 7.74/2.9/500 and field of view (FOV) 260, which gives isotropic 
voxels of 1 × 1 × 1 mm3). For protocol 1, the following parameters were used: TR/TE/TI 
6.8/2.95/450 and FOV 256, giving isotropic voxels of 1 × 1 × 1 mm3. Thereafter, MRS data 
acquisition was performed where 1H-MRS-spectra of protocol 1 were obtained from the left and 
the right STG (voxel size 24 × 40 × 30 mm3) and ACC (voxel size 40 × 40 ×25 mm3) by using a 
single-voxel point-resolved spectroscopy (PRESS) sequence (TE/TR = 35 /1500ms, 128 
repetitions), followed by a Mescher-Garwood PRESS (MEGA PRESS) sequence (TE/TR = 
68/1500 ms, 128 repetitions), however MEGA-PRESS measures, i.e. GABA, is not included in 
the current thesis. 
 
 
Figure 3: Images of placements in Protocol 2: left IFG (to the left) and left STG (right) in 
transverse view. The green box demonstrates the placement in one representative subject 
mapped onto a standard template. The orange and the red indicate 95% and 60% confidence 
regions for the placements across the patient group. 
 
Measurement of protocol 2 were conducted from the left IFG (voxel size 24 × 38 × 28mm3) and 
left STG (voxel size 24 × 30 ×31mm3) obtained by using the PRESS and MEGA-PRESS sequences 
with identical parameters as above except that the MEGA-PRESS repetition number which was 
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set to 192. Voxel localization was performed according to anatomical landmarks using the T1-
weighted structural image. Unsuppressed water reference spectra (eight repetitions) were acquired 
automatically after the acquisition of water-suppressed metabolite spectra in both protocols. A 
scanner up-grade was done between data collection of protocol 1 and 2, including a change of 
head-coil from 8 to 32 channels.  
MRS data processing. 
MRS data from the PRESS sequence were analyzed using the LCModel (Provencher, 2001) 
version 6.3-1J (Stephen Provencher, Inc., Oakville, ON, Canada), with the standard basis-set 
incorporating components from 15 metabolites (Alanine, Aspartate, Creatine, γ-aminobutyric acid, 
Glucose, Glutamine, Glutamate, Glycerophosphorylcholine, Phosphorylcholine, Lactate, myo-
inositol (mI), N-acetyl aspartate acid (NAA), N-acetylaspartylglutamate, scyllo-inositol and 
Taurine). As a standard on the GE implementation of the PRESS sequence, unsuppressed water 
reference spectra were acquired automatically after the acquisition of water-suppressed metabolite 
spectra, and averaged before being processed and analyzed.  
Diffusion Tensor imaging acquisition 
White Matter (WM) diffusion was studied with Diffusion Tensor Imaging (DTI). In each 3D brain 
volume, the values indicated the strength of a certain type of diffusion-coefficient, Fractional 
anisotropy (FA), in each voxel.  
DTI Data Processing 
The DTI images were preprocessed with FMRIB Software Library’s (FSL, version 4.1.2, 
fmrib.ox.ac.uk/fsl) (Smith et al., 2004). The DTI images were motion and eddy current corrected. 
Voxel wise statistical analysis of the DTI data was carried out using Tract-Based Spatial Statistics 
(TBSS) procedure (Smith et al, 2006), a part of FSL. For the next step, the FA data were aligned 
into 1 mm × 1 mm × 1 mm Montreal Neurological Institute (MNI) 152 Space using the FMRIB's 
Nonlinear Image Registration Tool (FNIRT). Then, the mean FA image (threshold of 0.25) was 
created and thinned to create a mean FA skeleton that represents the centers of all tracts common 
to the group. Each subject's aligned FA data was then projected onto this skeleton and the resulting 
data were fed into voxel-wise cross-subject statistics. Subjects with poor image quality due to 
subject motion or other visible image artefacts (e.g. due to metal) were removed. Finally, the JHU 
 GLIAL ACTIVATION AND NEUROINFLAMMATION IN SCHIZOPHRENIA 
27 
White-Matter Tractograpy Atlas was used to identify the tract content of the observed clusters with 
significant group and voxel placement interaction effects (Smith et al., 2006).  
 
Laboratory. 
The blood sample consisted of measures and analysis of cytokines Tumor-Necrosis Factor alpha 
(TNF-α), Interleukin-1beta (IL-1β), IL-6, IL-10 and C-reactive protein (CRP). The blood specimen 
were drawn from the participants in the fasting state between 8 and 9 PM by trained nurses and 
collected at serum gel tubes, centrifugation at 3300 rpm for 10 minutes, pipetted and stored at 
minus 40 centigrades, then moved without being thawed and stored at minus 80 centigrades until 
analysis. Cytokine measurements were done with the Luminex Screening Human Magnetic Assay 
from R&D Systems, Inc., 614 McKinley Place NE, Minneapolis, MN 55413 
Statistical Analyses 
Descriptive statistics on the datasets were run with IBM SPSS Statistics for Windows, Version 
24.0. Armonk, NY: IBM Corp. 
Group differences in glial markers. 
The glial markers myo-inositol (mI), N-acetyl aspartate (NAA) and choline (Cho) with group 
(patient versus control) and voxel placement were subjected to statistical analysis using linear 
mixed model regression models. This procedure enables to fit mixed effects models to data 
samples from normal distributions. The analysis was run with the different glial markers separately 
(see models in results), with the fixed factors group and voxel placement, and random factor 
subject. 
Glial marker predict symptom severity. 
Exploratory analysis examined the relationship between glial markers and symptom severity in 
patient group using mixed model analysis, with the variables PANSS positive and negative total, 
and voxel placement as fixed effects and again voxel placement as repeated effects. 
Cytokines predict glial markers. 
Hierarchical multiple regression was run separately for NAA, mI and Cho with predictors fitted 
into 2 models: (1) age, sex, medication group (how far in treatment), symptoms, (2) TNF-Alpha, 
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IL6, IL10, IL1b, and CRP to test if glial markers could be predicted by the theorized variables, 
with particular interest in inflammation markers’ ability.  
DTI data and glial markers. 
After processing the DTI data creating FA values in TBSS, and matching the subjects with MRS 
data, 6 subjects was excluded due to missing data, leaving a total of 109 subjects to be analyzed. 
After the files were decompressed to suitable file type, tests were conducted to investigate if glia 
markers are related to regional changes in FA and whether this differ between patients and controls. 
Non-parametric permutation-based PALM package, was applied with 10000 permutations and 
threshold-free cluster enhancement (TFCE), with a significance level of p <.01 (family-wise error 
FWE corrected) adjusted for multiple comparisons by using the null distribution of the maximal 
voxel-wise test statistic (Winkler et al., 2014). A multiple regression model was set up containing 
the group effect (patient/control), the three metabolites (NAA, mI, Cho) and three 
group*metabolite interaction terms. Age, sex and scanner version were entered as covariates. 
Furthermore, for significant group*marker interaction clusters, FA values extracted from these 
clusters and tested only within patient group whether there is symptom severity effects. 
Data management 
Processing and analysis was performed on secure servers. 
  




Group differences in glial markers 
Description for the means of the glial markers Choline, N-acetyl-aspartate acid (NAA), and Myo-
inositol (mI), for all 154 patients and controls across voxels, are displayed in Table 3. The means 
were computed from all four regions measured; left Superior temporal gyrus (L STG), right STG, 
L inferior frontal gyrus (L IFG) and anterior cingulate cortex (ACC), resulting in one mean variable 
for each glial marker, and a four-level voxel placement variable. A linear regression model 
procedure was fitted to the data, with the glial markers as dependent variable, and group and voxel 
placement as fixed factors. 
 
Table 3: Description of the glial marker values for patients and controls across regions 
 Glial marker Min Max Mean Median SD 
Patients Cho 1,10 3,71 2,14 2,14 ,49 
NAA 8,83 18,98 13,93 13,97 1,92 
mI 3,51 9,72 6,51 6,50 1,27 
       
Controls Cho ,91 3,16 2,04 2,05 ,44 
NAA 8,74 19,32 13,85 13,95 1,69 
mI 1,49 11,48 6,34 6,40 1,45 
 
Choline. 
The fixed effects model estimated a significant main-effect of group on choline levels (F (1, 
144,153) = 5.899, p = .016), with higher choline in patients (M = 2.14 SD = .49) compared to 
matched controls (M = 2.05, SD =.44). The median values seen in table 1 indicate close values to 
the means. Calculating the Cohen’s d for the size of the differences yielded d = 0.18.  




Figure 4: Box plot demonstrating group differences in choline levels across regions. Top box’s 
midline is demonstrating patients mean, which is visibly higher compared to the lower box’s, 
representing control’s mean. The lines are representing the range of variance, and in the 
patients’ measures, there are also two outliers can be identified.  
 
No significant interaction-effects were found for the group x voxel placement analysis (F (3, 120. 
611 = 1.410, p = .243). The main effect of voxel placement was however significant (F (3, 120, 
611) = 173.089, p< .001) identified to anterior cingulate cortex.  
NAA. 
For NAA, there was no significant results for main-effect of group (F (1, 136,704) p = .484. For 
voxel placement, the fixed effects was significant F (3, 130,230) = .22.825, p = <.001.  
There was no significant interaction effect for group x voxel, F (3, 130,230) =, p =.636.  
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mI. 
There was no significant main-effect on mI by group, F (1, 141,717) = 1,300, p = .256, or main-
effect for voxel placement, F (3, 130,263) = 88.217, p = .345. Finally, there was no significant 
interaction-effect for voxel placement and group, F (3, 130,263) = .155, p = .926.  
Glial markers and Symptoms 
The next set of analyses involved patients only. A linear multilevel mixed model was fitted to the 
data with PANSS (symptom severity index) measures and voxel placement as fixed effects, and 
glial marker as the dependent variable. The description of the severity index can be seen in table 
4 below.  
 
Table 4: Description of PANSS severity scores for the patient population in the current sample. 
There is overall a higher positive total scores compared to negative total scores. 
N = 61 Min Max Mean Median SD 
Positive Total 12 38 21,38 21 5,04 
Negative Total 7 33 17,17 17,50 5,81 
 
Choline. 
There were non-significant main-effect of Cho for PANSS positive total index (F (17, 104) = 
1.115, p = .350) and PANSS negative total index (F (18, 104) = .802, p = .694), with the only 
statistically significant effect being voxel placement main-effect (F (3, 104) = 41,421, p < .001). 
Finally, no significant interaction-effect for voxel placement on the total were found, pos*voxel, 
F (40, 12.659) = 1.704, p = .154), neg*voxel, F (43, 12.206) = 1.214, p = .373), indicating no 
significant difference in the relationship between choline and PANSS scores in the different 
regions.  
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NAA. 
There were non-significant main-effect of NAA both for PANSS positive, F (17, 25.108) = .310, 
p =.992) and PANSS negative total scores, F (18, 26.111) = .398, p = .977) for the 59 subjects with 
data eligible for analysis. There were further non-significant main-effects of voxel placement for 
PANSS positive total scores, F (33, 5.386) = 1.041, p = .540) and for negative total scores (F (35, 
4.729) = .1.294, p = .431), indicating that there were no significant difference in the relationship 
between the NAA and PANSS scores in the different regions. 
mI. 
Finally, the same lack of significance of mI on PANSS positive total (F (17, 256.903) = .302, p = 
.997) and negative total (F (18, 234,179) = .168, p = 1,000) was observed. No interaction-effect 
was observed for voxel placement and the total scores, pos * voxel (F (33, 38,051) = .870, p = 
.656) nor neg*voxel (35, 28.788) = .785, p = .754). Significance was observed for voxel placement 
main-effect, F (3, 34000) = .001, p < 001.  
Cytokines and CRP predict glial markers, only patients.  
Hierarchical multiple regression was run using the glial markers as dependent variables and with 
fitted Model 1 including the covariates given in table 6 below. We continued the hierarchical 
regression analysis by fitting model 2 using cytokines.  
 
Table 5: Cytokine and CRP description in patients on visit 1. The description of the values 
shows a wide variance for the 21 patients in the minimum to the maximum values indicated by 
the standard variation column to the right.  
 N=  21 Min Max Mean SD 
IL-1B ,80 424,14 49,12 87,88 
TNF-a 1,20 459,92 47,75 93,93 
IL-6 1,55 566 53,34 140,32 
IL-10 ,22 54,43 22,49 18,251 
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CRP N = 59 ,0 29,70 1,72 3,57 
  
The glial measures applied derived from L STG due to most number of measures in sample, 
providing best power (N=75).  
 
Table 6: Regression models for glial marker level prediction. Model 1 consist of the known 
moderating factors in schizophrenia. Model 2 consists additionally of the cytokines and CRP.  
Model 1 Model 2 
PANSS negative total, PANSS positive total, 
medication type, gender, age, and scanner 
version 
All variables in model 1, and in addition cytokines: 
IL-10, IL-6, IL-1beta, CRP, TNF-alpha 
Choline. 
Model 1 gave us an R2 value of 512, and an adjusted R2 of .275. Model 2 obtained a R2 of .795 
and adjusted R2 of .474. We compared model 1 with model 2, and found model 1 to explain 51.2% 
of the variance. The addition of the cytokines led to explaining additional 27, 9% of the variance, 
having the full model explaining 79,5% of the variance. Adding the cytokines (model 2) did not 
statistically significantly increase r2, F (5,7) = .1,909, p = .211. The full model was not statistically 
significant in predicting glial levels, R2 = .892, F (11,7) = 2,474, p = .119, adjusted R2 = .474. 
 
Table 7: Coefficients table: for cytokines regression analysis on choline. Only PANSS positive is 
significant to choline.  
  Model 1  Model 2  
Variable B Beta Sig. B Beta Sig. 
(Constant) .913  .079 1.482  .033 
Gender -,226 ,346 .133 -,385 -,591 .023 
Age ,009 ,364 .187 ,008 ,340 .404 
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Fmri week -,006 -,018 .950 ,033 ,102 .735 
Allocated 
medication 
-,055 -,139 .616 -,064 ,142 .666 
PANSS 
Positive 
,048 ,629 .018* ,034 ,437 .251 
PANSS 
Negative 
-,011 -,195 .500 -,017 -,285 .529 
IL-6    <0,001 -.004 .991 
IL-10    -.015 -.798 .156 
IL-1beta    .010 .828 .508 
CRP    .032 .214 .418 
TNF-alpha    -.007 -.437 .768 
NAA. 
Model 1 gave us an R2 value of .336 and an adjusted R2 of .005. Model 2 obtained a R2 of .588 
and adjusted R2 of -.059. We compared model 1 with model 2, and found model 1 variables 
explaining 33.6% of the variance, and the addition of the cytokines led to additional 25.2%, 
explaining 58.8% of the variance. However, adding the cytokines (model 2) did not statistically 
significantly increase r2, F (5, 7) = .856, p= .553. The full model was not statistically significant 
in predicting glial levels, R2 = .588, F (11, 7) = .909, p = .575, adjusted R2 = -,059. 
 
Table 8: Coefficients table for cytokines regression on NAA. PANSS positive is significant. 
  Model 1  Model 2  
Variable B Beta Sig. B Beta Sig. 
(Constant) 8,54  .043 14.46  .031 
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Gender .192 .043 .866 -.481 -.109 .717 
Age .014 .086 .783 -,004 -,026 ,963 
Fmri week -
.351 
-.163 .624 ,224 -,344 ,516 
Allocated 
medication 
.033 .012 .970 -,930 -,344 ,516 
PANSS 
Positive 





-.095 .788 ,109 ,277 ,663 
 
IL-6    -,010 -,702 ,229 
IL-10    ,003 ,023 ,975 
IL-1beta    ,178 2,214 3230 
CRP    ,150 ,149 ,685 
TNF-alpha    -,278 -2,437 ,226 
mI. 
Model 1 gave us an R2 value of 548, and an adjusted R2 of -.050. Model 2 obtained a R2 of .823 
and adjusted R2 of .172. We compared model 1 with model 2, and found model 1 variables 
explaining 30% of the variance, and the addition of the cytokines led to additional 37,8% 
explained, with the full model explaining a total of 67,8% of the variance. Adding the cytokines 
(model 2) did not statistically significantly increase r2, F (5, 7) = .1,642, p =.266. The full model 
was not statistically significant in predicting glial levels, R2 = .823, F (11, 7) = .1,339, p = .360, 
adjusted R2 = .172. 
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Table 9: Coefficients table for cytokines regression on mI. None of the coefficients are 
significant. 
  Model 1  Model 2  
Variable B Beta Sig. B Beta Sig. 
(Constant) 3.866  .097 4.452  .136 
Gender -.208 -.085 .749 -.731 -.298 .281 
Age .028 .299 .358 -.003 -.028 .955 
Fmri week -.696 -.581 .106 -.844 -.705 .095 
Allocated 
medication 
.600 .400 .241 1.168 .788 .124 
PANSS 
Positive 
.090 .313 .282 .156 .542 .256 
PANSS 
Negative 
-.008 -.039 .911 -.072 -.329 .560 
IL-6    -.003 -.365 .465 
IL-10    -.007 -.102 .876 
IL-1beta    -.065 -1.451 .363 
CRP    .215 .384 .259 
TNF-alpha    .051 .810 .663 
 
DTI and glial markers 
Permutation analysis was run in PALM to test the relationship between the glial markers and group 
(patient/control) and FA levels. Main effects and group*glial marker interaction effects were 
included in the model. Glia markers were obtained from L STG, due to all participants undergoing 
measures from this voxel. Age, gender, and scanner version were added to the analysis as 
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covariates. The results yielded no main-effect for group or glial markers in L STG. However, at 
P<.01, scanner version gave significant main-effect results, an expected finding. 
 
 
Figure 5: The Trends-levels for mI in L STG x Group interaction effects in Superior 
Longitudinal Fasciculus (SLF). The black marks are indicating the placement of the trend-level 
effects, in coronal view (top left), sagittal (top right) and transverse (bottom left) view. The 
clusters were identified as SLF. 
 
Despite no statistically significant findings at p<.01, there were interesting trends in the analysis 
of the FA values for the mI in L STG x group interaction effect at p<0.07. Mainly the results were 
observed in the left hemisphere (see Figure X, Table N) fronto-temporally. 
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As Table 10 shows, the cluster peak was at MNI coordinates -31, 5 ,34, and the closest white 
matter tract was left superior longitudinal fasciculus (4% overlap). Overall, the probabilities are 
low due to the tracts in question being large while the identified cluster are a minor part. The 
cluster consisting of 4% superior longitudinal fasciculus (SLF) in both identified voxels.  
Further, mean FA values were extracted from the cluster to explore the direction of the interaction. 
Pearson correlation revealed significant negative correlation between FA and mI in L STG in 
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Figure 6: Interaction effects for mI in L STG and FA mean in patients. The direction of the 
association between mI and FA is negative, as indicated by the direction of the regression line. 
 
In Figure 6, the scatterplot indicated the negative correlation between mI and FA in patients of 
lower FA and higher mI. The x-axis demonstrate the mI in L STG levels for patients, ranging from 
3.2 to 8.9 mmol/L, and the y-axis show the FA values ranging from .40 to .75. The main effect of 
mI increases as FA degree lowers, and the interaction of the effect is different between the groups, 
as indicated by the direction of the correlation. The interaction effect of mI from left superior 
temporal gyrus (L STG) is different between patients and controls. In patients FA decrease with 
increasing mI, while in controls, as seen in the figure 7 below, the FA increase with increase in 
mI.   
 
 
Figure 7: Interaction effects for mI in L STG and FA mean in controls. The effect was positive as 
indicated by the regression line, indicating increase in FA and increase in mI. OBS expand. 
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In figure 7, the direction of FA increase with increase in mI is seen.  The x-axis demonstrate the 
mI in L STG levels for patients, ranging from 1.6 to 8.6 mmol/L, and the y-axis show the FA 
values ranging from .40 to .68.  
 
Table 11: Description of Fractional Anisotropy (FA) values and myo-inositol (mI) levels in left 
superior temporal gyrus (L STG) in patients and controls.  
  FA (N = 52) L STG mI (N=75) 
Patients .52 (SD =.06) 5,77 (SD =1,22) 
Controls .54 (SD = ,05) 1,37 (SD = 1,37) 
 
The FA values were slightly lower in patients compared to controls, while mI was higher in 
patients than controls (See table 11).  
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Findings and Discussion 
 
 
Summary of Findings 
The current study investigated glial marker activation and neuroinflammation markers activation 
in schizophrenia by hypothesizing glial activation differences between participants and matched 
controls, and exploring the relationship between the markers and to symptoms. As hypothesized, 
there were group differences, with choline being statistically significant higher in patients across 
the brain compared to their healthy matches (low effect size). However, no significant group 
differences were found for N-acetyl aspartate acid (NAA) or myo-inositol (mI), yet all glial 
markers were higher in patients than controls on visual inspection of the means, yet considerably 
small effect sizes, d = .005 and d = .12, respectively for NAA and mI (very low effect sizes). Voxel 
placement main-effects were significant for NAA, and located to anterior cingulate cortex (ACC), 
which warrants future exploration of concentrations differing between brain regions. Further, the 
glial markers were tested to see if pro- and anti-inflammatory cytokines and CRP could predict 
them, with no statistically significant findings. In addition, dependency in glial cells to symptom 
severity and type indexed by PANSS total positive and negative scores was modelled and tested, 
with no significant findings. Overall, none of the models fitted the data in that they were not 
predicting the outcomes on the dependent variables. However, there might be several reasons for 
that which will be discussed further and are source for limitations in the study. The final analysis 
yielded trend-levels myo-inositol (mI) and group interaction-effects of fractional anisotropy (FA) 
values in the cluster identified. Inspecting the group effects revealed a negative correlation in 
patients between mI in left superior temporal gyrus (L STG) voxel placement and FA, meaning 
when mI increase the FA values goes down. In controls, the relationship was positive. Significant 
impact of the change of scanner version, i.e. image quality, were identified, indicating the 
importance to include such changes in analysis, like the current project have.  
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Group differences in glial activation 
 
The key finding in the current project is the group differences in glial activation in schizophrenia 
patients compared to matched controls.  
The significantly higher mean of choline concentrations across the brain in schizophrenia 
patients compared to matched controls, is finding in line with previous evidence of elevated 
choline levels in patients compared to controls (Bustillo et al., 2002).  The finding of elevated 
choline in patients has previously been understood in the light of immune mechanisms at play, as 
there is more choline in glial cells compared to neurons (Gill et al., cited in Plitman et al., 2015). 
Overall, the findings could be understood to have implications for glial dysfunction. Another study 
also found higher Choline levels for first-episode psychosis (FEP) patients compared to controls 
(Plitman et al., 2018), which was also found at in a longitudinal study conducted by the same 
research fellowship (de la Fuente-Sandoval et al., 2011; de la Fuente-Sandoval, 2013). Bustillo 
and colleagues (2002) suggested high choline concentrations to reflect dysfunction in neuronal 
phospholipid membrane formation, slow glucose metabolism and/or larger than normal 
acetylcholine transmission.  
There are no robust distinct metabolite levels established in schizophrenia, however 
effect sizes are interesting to evaluate for the understanding of the group differences found. In 
the current situation, the effect size (ES) for the group difference in choline was d = .018, which 
is considered small. However, as Cohen himself strongly emphasizes, it is not just the magnitude 
of the effect that is of interest, but the practical and clinical value too, and could be understood as 
“the extent of meaningful change in participants lives” (Cohen, 1979 cited in Durlak, 2009, p 
917). Applied to the current situation, it is not possible to determine the practical or clinical 
benefits of the choline changes, as Durlak writes, “it is worth a try in order to capture the full 
meaning of research findings” (Durlak, 2009, p. 918). Hence, it is attempted to speculate in the 
implications of the results; exploring choline mechanisms, which could theoretically reach 
around 10% improvement in the patient population, calculated from the current ES. A number of 
significance regarding improvement in daily functioning. 
Typical medication for bipolar disorder have tended to be lithium which is known to inhibit 
choline transportation which is thought to be the effective part of the effect treatment in rapid-
cycling bipolar disorder (Stoll et al., 1996, cited in Moore et al., 2002). Such previous findings and 
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interpretation might also be speculated to translate to schizophrenia treatment. Bipolar and 
schizophrenia are known to have overlapping symptoms and emerging evidence points to shared 
genetics and phenotypes (Lichtenstein et al., 2009). In bipolar disorder, the adrenergic-cholinergic 
hypothesis postulates that the depression component is due to adrenergic underactivity and 
cholinergic overactivity, which results in increase of acetylcholine. Further, mania is associated to 
adrenergic overactivity and cholinergic underactivity (Moore et al., 2002). As the currently used 
dopamine receptor-blocking antipsychotic medication are found effectful for decreasing 
hallucinations and prevent major relapse, but not so much cognitive symptoms (Kroken et al., 
2014), the finding of higher choline in patients than control is highly interesting in the light of 
exploring new treatment targets that might be promising to be effective on the cognitive and 
negative symptoms.  
The finding of voxel placement main-effect from anterior cingulate cortex is also found in 
another recent study, where ACC was found to have lower levels of NAA compared to healthy 
controls (Reid et al., 2018). However, the direction is missing in the current study. Findings of 
reduced NAA in schizophrenia in medial temporal regions together with reduced DTI anisotropy 
index has as previously presented been interpreted as lowered connection and myelination in 
axonal bundles (Tang et al., 2007), and is therefore indicated as a glial marker. Similar to the 
current study, Plitman and colleagues (2018) found no differences between patients and controls 
in  NAA concentrations,  which was interpreted in the potential light of the patients being early in 
illness progression, subsequent to neuronal loss if NAA could be understood as an indicator for 
neuronal injury (Plitman et al., 2018). However, as earlier pointed out, due to NAAs ability to 
recover it should rather be viewed as a surrogate marker of neuronal health and dysfunction, rather 
than loss (Dwyer et al., 2018). Hence, such findings could be interpreted as a chronological 
development in metabolite level expression differences during illness progression. The changes in 
levels could speculated to occur in order as Choline is found being both early in the progression 
as indicated by the findings in FEP population (Plitman et al., 2018), and in the current thesis the 
sample selection is not limited to early stage participants. As Plitman argue, other study’s findings 
of group differences in NAA is due to its occurrence later in the illness progression as NAA 
dysfunction could be due to imbalance in glutamate-GABA which result in excitotoxicity in 
combination with glial activity (Walterfang, Velakoulis, Whitford and Pantelis., 2011).  
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For mI, in neuroinflammation mI reported increased and is speculated to be due to 
hypomyelination, similar to the processes in MS, however, there were no significant group main-
effects identified, yet group x voxel placement effects on FA, which will be discussed later on. 
Furthermore, several factors are identified to be considerably mediating the metabolite 
concentrations, such as illness progression. Several previous studies have included participants in 
different stages of the disorder, FEP persons together with chronic patients like in the current 
project, however, important variations might come forth regarding the metabolite profiles across 
illness progression, duration and severity.  
A recent review suggested schizophrenia to be conceptualized as a syndrome consisting of 
“several disease phenotypes with a range of distinct underlying pathologies” (Kroken et al., 2019, 
page 2.). Immune mechanisms could be one of them, yet also related to energy metabolism or 
synaptic dysfunctions, and with choline being related to several processes that are glial-derived, it 
could seem unclear which specific mechanisms its levels are reflecting. Still, the findings could be 
speculated to have implications as a medication target worth exploring, which might be of practical 
significance.  
Clinical Symptoms and Glial Markers 
Contrary to expected the results from the analysis indicated little information from the three 
glial markers to the symptoms load index, both for positive and negative total scores. Furthermore, 
voxel placement yielded also little information about the PANSS values. Despite not statistically 
significant, the mixed model results could be speculated to that choline was better predicted by 
negative symptoms, than positive, findings that could arguably be in line with the suggestion of 
further explorations of choline target for negative symptoms, similar to the treatment in bipolar 
disorder as discussed in previous paragraphs. The results for myo-inositol indicated very poor 
(.997 and 1.000) prediction be the positive and negative symptoms respectively. For NAA, positive 
symptoms yielded very poor fit in the concentration prediction, with slightly better fit for negative 
symptoms.  
The lack of findings of the glial markers predicting clinical symptoms could be due to 
several reasons. Unpublished studies on the same dataset as the current found significant 
associations when the symptoms were into specific analysis on metabolites GABA and Glutamate, 
and divided psychosis item on PANSS divided into high and low hallucinators (Hjelmervik et al., 
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2019, in prep). Several authors warrants for further research with exact examination of the 
symptoms to their empirically and theoretically implied biological mechanisms, providing clearer 
indications for the interpretations of findings. This seems particularly important regarding 
exploration of glial marker activation as the current thesis are attempting to present in the 
introduction the wide range of glial cell functions, not merely inflammation. In addition, the 
different fit in the glial markers could be interpreted to indicate the importance of distinguishing 
the different classes’ glial activation and their associations to different aspects of the schizophrenia 
syndrome. In this study, PANSS positive was found as a significant coefficient to choline that was 
significantly higher in patients. NAA also had significant coefficient findings for PANSS positive 
but no group differences, and finally no associations were identified to mI. However, previous 
studies found decreased mI to correlate to depressive symptoms (Chiapelli et al., 2015).  
Mitterauer (2011) describes alternative dimensional descriptors for schizophrenia dividing 
into psychotic dimension, disorganized dimension and a negative deficit dimension. Perhaps two 
of the glial markers could be understood to represent some of these dimensions, with choline 
potentially being associated to negative symptoms and mI to the disorganized. The latter is further 
discussed under the findings from the DTI analysis. Mitterauser’s (2011) model suggests that the 
lack of boundaries in information processing for patients are due to glial-neuronal interactions, as 
other illnesses associated to glial activation (i.e. inflammation) like previously mentioned 
inflammation-associated multiple sclerosis. Multiple sclerosis (MS) and rheumatoid arthritis are 
most indicated as more affected by inflammation processes than schizophrenia, distinguishing the 
illnesses in the current state of research as higher grade and lower grade inflammation, 
respectively. Interestingly, MS is not only indicated to have a strong inflammation component 
interpreted due to findings of elevated immune mediators, the same as the ones applied in the 
current thesis, and progressive demyelination, yet also share with schizophrenia cognitive 
impairments and psychotic symptoms, established in the diagnostic manual DSM (Chiaravalloti 
and DeLuca, 2008).  
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Cytokines Predicting Glia Markers  
None of the glial markers was found predicted by the cytokines or CRP.  Previous meta-
analysis found that 40% of patients had some form of inflammation (Osimo et al., 2018) which 
gives source for the expected relation between the markers. Furthermore, in another summary of 
99 studies, it was found that in 50% of the included studies investigating the cytokines IL-6, TNF-
alpha, and IL-1beta, was found to differ between patients and controls (Rodrigues-Amorim et al., 
2017). However, there are crucial technical issues concerning the analysis. 
First, it was believed that the analysis would lack in power as only a number of 21 patients 
passed the quality test for the cytokines measures. The low number would have low statistical 
power, yet be able to give potential interesting insight into the relation between the markers despite 
not being able to give an estimation of more complex models with several parameters. It was 
considered that despite the technical issue with so few measures, the measures were believed to be 
representative as it was random missing data and not a matter of drop out. Drop outs are an issue 
in research, particularly for serious illnesses, and is typical in longitudinal studies, often with the 
results of that the most ill is not represented.  
After analysis, great discrepancies in the measures for both cytokines and CRP, beyond what is 
considered possible range was observed. Frydecka et al (2018) did meta-analysis on both first 
episode (FES) and multiple episodes schizophrenia (MES) patients and identified the means in 
both cohorts. For instance, they identified IL-1beta to have a mean of 1.3 with 0.3 standard 
deviations in FES and for MES the mean was 1.5 with 0.5 standard deviations. In the current 
sample, the mean yielded 49.12 with 87.88 standard deviations.  
It was identified that this was due to technical issues, as visual inspection of the dataset 
identified the variation to vary with the point of date measured. It was later confirmed as technical 
issues with the screening assay was found to skew proportions of the blood samples values to be 
a lot higher than what they typically range. If interpreting the current findings, the data is poorly 
fitting the models indicating that that it is difficult to predict glial markers by cytokines and that 
variance in the glial markers is not well explained. However, as it known that the blood samples 
are unreliable, interpretation of results with cytokines and CRP in the current master thesis will of 
course be faulty.  
Usually, the interpretation of the regression outcome is to look at the increase of R and 
whether it is significant.  Low Rs indicate poor model fit to the data, or that the covariates are not 
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contributing with much information that would increase the dependent variable. This would aid in 
the tradition for interpreting hierarchical regression analysis outcome when comparing the models. 
The results’ low R’s indicate poor model fit overall. The standard is to determine whether the 
model is a good fit for the data, and to finally inspect the coefficients unique contribution to the 
model. 
However, the coefficients tables’ could be worth mentioned for the other variables in the 
models. The output is understood as the significance levels of each coefficients indicate an effect 
when far enough from zero. For choline, significance was found from PANSS positive (.018), 
indicating that choline increase with .048 for each point on the PANSS positive. This finding is 
questionable, as the same associations has not been found in the mixed model analysis. The further 
coefficients were not significant, however, they suggests some tendencies. For instance, the 
choline levels decrease with the older scanner version and slightly increase with age. Furthermore, 
gender also showed tendencies, in line with previous studies have also found gender differences 
in choline, with particular variations in resonance in females depending on the menstrual cycle 
(Hjelmervik et al., 2018). For NAA, none of the coefficients was significant in model 1. However, 
it could be speculated if the results indicate that with increase in PANSS positive total scores, there 
is a rise in NAA, and decrease with PANSS negative total score increasing. In addition, the levels 
seems to increase with age and if being male. For mI, there were no significant coefficients effects. 
Trend-level mI x Group Interaction Effects on FA 
There was no replication of other studies’ findings of significant group differences in mI; 
however, there was an interesting trend-level (0.07) in the group and mI interaction effect on FA. 
In previous findings of elevated mI, this was interpreted as hypomyelination, and decreased mI 
have been found correlated to depressive symptoms (Chiapelli et al., 2015).  Furthermore, the 
negative correlation in patients between mI in L STG and FA value could be suggested to imply 
that in schizophrenia subjects, when mI increase, the FA values goes down. The decreased FA 
values in patients compared to controls are perhaps reflecting aberrant tissue environment. The 
previous finding by Chiapelli and colleagues (2015) and the current thesis’ findings could be 
speculated to be of shared processes between mI and FA, which seems to be some sort of imbalance 
in patients compared to controls.  The imbalance could be interpreted in how mI is thought of as a 
reflection of cell density, and FA as degree of coherence in tracts. However, if the data allowed to 
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be modelled, the plots would align in an obvious pattern. Furthermore, there was no obvious 
relationship between mI and FA on the visual inspection of the scatterplot of the data.  
In line with previous studies, the FA was overall lower in patients compared to controls. 
The lower FA is found across illness progression in FEP and chronic patients compared to controls 
(Szeszko et al., 2008). Mitterauer (2011) propose that the incoherence hypothesis of schizophrenia 
is based on the consistent findings of decrease or loss of oligodendrocytes and the myelin sheath 
that in normal situations wrap axons. The axons conduct information, and when normal the brain 
is able to compose and construct meaning from a wealth of input. In cases of demyelination, the 
oligodendrocyte-axon system cracks and the brain is unable to generate the information received 
into categories. Mitterauer (2011) describes alternative dimensional descriptors for schizophrenia 
dividing into psychotic dimension, disorganised dimension and a negative deficit dimension. It 
could be speculated if the two of the glial markers could be understood to represent two of these 
dimensions, with choline potentially being associated to negative symptoms and mI to the 
disorganised dimension, as abnormalities in white matter may be responsible for symptoms of 
incoherence. 
The trend for the interaction effect was identified in clusters mostly in superior 
longitudinal fasciculus (SLF). The superior longitudinal fasciculus is the fiber bundle that link 
posterior parietal cortical areas to different frontal cortical regions (Karlsgodt et al., 2008). 
Despite the values derived from the cluster analyses indicate the probabilities are quite low (4%), 
it could be due to the identified white matter tract is quite large, and the cluster is only taking up 
a small part of it. The involvement of superior longitudinal fasciculus (SLF) is recurrently 
implied to be a region importance in schizophrenia.  Alterations in SLF are indicated as robust in 
the early progression of the disorder (Ruef et al., 2012 cited in Karlsgodt et al, 2008), as well as 
in bipolar disorders with manifesting psychosis (Lin et al., 2011 cited in Karlsgodt et al., 2008). 
Furthermore, the findings have been replicated in high-risk individuals (Karlsgodt et al., 2008). 
The current findings are suggestive to SLF as a region with alterations in schizophrenia, and to 
be associated with mI measured in L STG, which warrants exploration in future studies.  
In conclusion, the current project suggest glial abnormalities in schizophrenia patients. 
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Limitations 
There are limitations in the master thesis. The current sample is not characterized as low 
(n = 154), however, due to quality issues, the number of valid measures are in some voxels down 
to 37. Furthermore, low sample sizes are not accurate in detecting subtle metabolite changes, 
whereas large ones are critiqued to be prone to detecting differences too small to have a clinical 
significance. Due to scanner update during the data collection period, there are differences in 
protocols which results in different number of measures between the voxels. As a reminder, for 
instance in L STG there are 119 measures for NAA (all participants), while only 52 in R STG. 
The missing measures limits the exploration of the voxel placements and measured metabolites 
in power.  
There are known covariates that could have benefitted the robustness of the findings if 
included. For instance, controlling for scanner version is supported by the significant main effect 
observed. Smoking is found to impact inflammatory markers (Fernandez et al., 2012) and obesity 
(Khandaker and Dantzer, 2016), hence, smoking status and BMI should be controlled for. 
Furthermore, so could the duration of illness and previous medication exposure, as these as 
repeatedly causing differences. 
In addition to the faults in the blood sample analysis, there are other features of the analysis 
models that could be critically discussed. The regression models have a relative large amount of 
variables, which could make analysis prone to Type 1 errors in multiple comparisons. With several 
variables added to the model at once, it could be that some of the added variables to contribute, 
but is cancelled out by the lack of information in the other variables in the model. An alternative 
could have been to add one variable at a time in the model.  
Traditionally, corrections for multiple comparisons like the Bonferroni has been the go-to 
solution. This method divides the alpha level .05 on the number of added variables. However, 
adding such a conservative correction on biological data might make the conclusions prone to 
Type 2 error, i.e. accepting the null hypothesis when there are actual differences. Imaging 
Statisticians Lindquist and Gelman, (2009) suggest that the whole issue of correction can be 
avoided if one multilevel model is builded from the start. In the current study, it is also attempted 
to build a model of glial activation markers and neuroinflammation markers in schizophrenia 
patients. Multilevel models are shifting estimates and intervals towards each other, and hence it is 
important to include covariates known to be implying in the topic like age for myelin.  
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One of the strengths of the current project is its attempt to build models informed by current 
practice and emerging findings, and therefore the individual variables’ contributions to the models 
are not reported as many of these variables single correlations are already much researched and 
established, without an overall model context.  
Theoretical limitations 
Most studies on inflammation in schizophrenia use mean or median due to this lack of 
established cut-off scores which usually is referred to healthy controls (Monastero & Pentyala, 
2017). Hence, the levels are only considered abnormal if they are aberrant from the controls if 
the values are differing around two Standard Deviations. This is problematic. In the current 
study, there was only measures for patients, which, given the measures were without technical 
issues, would allow only for investigation of regression effects and not effect size.  
It is found that there will be revealed differences among individuals when the level of the 
proteins reach a certain number. In a study cut-off level of CRP was set to 3.8 mg/L, which then 
yielded significant correlations to PANSS positive symptoms (Weiser et al., 2014 cited in Kroken 
et al., 2019). Further research on the current data set could have potential to reveal associations 
with symptom severity as other studies have found if the sample was grouped into subtypes based 
on CRP levels, i.e. low, medium, and high. Interestingly, following the previously mentioned 
study, other researchers are applying the same value as inclusion criteria for individuals recruited 
to test the effect of immune-modulating drugs. This might be a first step to a consensus on a cut-
off score. Despite brain imaging techniques great ability to investigate microstructure and chemical 
changes, proteins like CRP and cytokines are far more cost-effective as most general practitioners 
offices have the ability to measure such.  
Future Research 
The choline elevations appear to be a promising area of investigation going forward. It would be 
interesting to explore to specific symptoms and the cytokines and CRP, as there is a new version 
of the blood analysis on the way. The trend-levels of mI and group interaction effects on FA is 
also interesting in the light of other studies findings on the blood brain barrier (BBB).Further 
exploration in the dataset was outside the scope of the current project. However, non-reported 
analysis in the dataset yielded replication of previous studies’ findings of positive correlation 
between S100B with mI within patients (Rothermundt et al, 2007). Chiapelli and colleagues (2015, 
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p 356) interpreted their finding to support “the hypothesis that activation of astrocytes may play 
an important role in the pathogenesis of schizophrenia at least in a subgroup of patients”. There is 
evidence of increased blood-brain barrier (BBB) permeability in patients (Najjar et al., 2017), and 
the effect of such is pro-inflammatory cells and molecules to enter the brain, which has already 
discussed in introduction and above about cytokines, can have adverse impact on tissue.  
Conclusion 
In sum, the current project cannot not contribute to the role of neuroinflammation in schizophrenia 
from the cytokine and CRP to glial cell markers or symptoms, however, it provides information of 
glial related-markers’ activation to be aberrant compared to match controls. Overall, the 
implications the current study is to further explore the glial dysfunction in schizophrenia, and 
encourage for further investigation of the potential immune signature, identify potential new 
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